Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Basel, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifi
Unveiling Novartis (NVS) Q1 Outlook: Wall Street Estimates for Key Metrics
10:16am, Thursday, 23'rd Apr 2026
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo
Evergreen Capital Management LLC Has $6.51 Million Stock Position in Novartis AG $NVS
04:45am, Wednesday, 22'nd Apr 2026
Evergreen Capital Management LLC boosted its stake in Novartis AG (NYSE: NVS) by 68.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi
Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade)
12:23pm, Tuesday, 21'st Apr 2026
Novartis AG ended 2025 on a high note. On February 27, NVS stock reached a 52-week high of $170.46. However, a correction began after that, in my view, partly due to a 33.2% quarter-over-quarter decli
Better Pharma Dividend Stock: Novartis vs. Merck
02:37pm, Friday, 17'th Apr 2026
Merck's outlook is bright despite challenges to its core franchises. Novartis is performing well despite a recent major patent cliff.
Farther Finance Advisors LLC Raises Stake in Novartis AG $NVS
04:12am, Friday, 17'th Apr 2026
Farther Finance Advisors LLC raised its holdings in Novartis AG (NYSE: NVS) by 87.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned
Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMs
10:00am, Wednesday, 15'th Apr 2026
BOSTON--(BUSINESS WIRE)--Instem announces the appointment of Szczepan Baran, VMD, MS, as Chief Scientific Officer to lead Instem's scientific and AI strategy.
Novartis AG (NYSE:NVS) Receives Consensus Rating of “Hold” from Brokerages
04:27am, Wednesday, 15'th Apr 2026
Novartis AG (NYSE: NVS - Get Free Report) has received a consensus rating of "Hold" from the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Two investment analyst
Big Pharma Deepens AI Ties. What It Means For Novo, Novartis.
12:52pm, Tuesday, 14'th Apr 2026
Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday.
Anthropic adds Novartis CEO Vas Narasimhan to its board
11:48am, Tuesday, 14'th Apr 2026
Anthropic on Tuesday added Novartis' Chief Executive Officer Vas Narasimhan to its board of directors, making him the first executive from the pharmaceutical industry to join the AI startup's go
Anthropic Adds Novartis CEO to Board
10:04am, Tuesday, 14'th Apr 2026
The startup behind the popular Claude chatbot and coding tool is eyeing a potential IPO as soon as this year.
East Hanover, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This come
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
04:11pm, Monday, 06'th Apr 2026
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
Eldred Rock Partners LLC Lowers Holdings in Novartis AG $NVS
05:17am, Friday, 03'rd Apr 2026
Eldred Rock Partners LLC reduced its position in shares of Novartis AG (NYSE: NVS) by 10.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (
Boston Common Asset Management LLC Sells 10,970 Shares of Novartis AG $NVS
05:04am, Tuesday, 31'st Mar 2026
Boston Common Asset Management LLC decreased its stake in shares of Novartis AG (NYSE: NVS) by 8.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securi
